Belzutifan vs. watchful waiting for slow-growing kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial compares two approaches for people with slow-growing, metastatic clear cell kidney cancer: taking a daily pill (belzutifan) or monitoring the cancer closely without treatment. The goal is to see if starting treatment early can help control the cancer longer than waiting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have clear cell kidney cancer that has spread to other parts of the body (metastatic) and was first noticed less than 12 months ago.
- You have not had any drug treatment for your kidney cancer, except maybe immunotherapy or targeted therapy that ended more than 12 months ago.
- Your cancer is slow-growing or low-risk (IMDC score 0 or 1) and your doctor thinks it's safe to watch it closely without immediate treatment.
- You are generally in good health (able to do daily activities) and your blood counts and organ function are within a safe range.
- You can swallow pills and have no major stomach or bowel problems that would affect how the study drug is absorbed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adding a gut health supplement (CBM588) to the immunotherapy drug pembrolizumab can help prevent kidney cancer from returning after surgery. It is for people with certain types of kidney cancer who have not had immunotherapy before.
This Phase 1 study tests whether a special PET/CT scan drug ([18F]PT2385) can help doctors see kidney cancer and related tumors. It may help guide diagnosis and treatment decisions, especially in people planning surgery or starting belzutifan.
This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.
This trial tests a new drug called belzutifan combined with a special imaging agent (89Zr-DFO-girentuximab) to see how they affect PET scans in people with advanced clear cell kidney cancer. It may help doctors better understand the cancer and guide treatment.
This study follows people with small, solid kidney tumors using active surveillance (regular monitoring) rather than immediate surgery or treatment. It may help you understand whether careful watching is a safe option for certain early kidney tumors.
This study tests whether closely monitoring small kidney tumors (less than 4 cm) with regular imaging is a safe and effective option for people who cannot or choose not to have immediate treatment. It involves a biopsy at the start to confirm the tumor type.
Hear when a new Active Surveillance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.